Date: 2/3/2022

Your Name: \_\_ Alexandra M. Giantini-Larsen

Manuscript Title: Novel Approaches to the Management of Patients with 5-15 Brain Metastases: A Narrative Review\_

Manuscript number (if known):\_\_CCO-22-15

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations,	None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	None
	testimony	
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or	None
	pending	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non-	None
	financial interests	

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date: 2/3/2022

Your Name: \_\_ Rupa Gopalan Juthani

Manuscript Title: Novel Approaches to the Management of Patients with 5-15 Brain Metastases: A Narrative Review\_

Manuscript number (if known):\_\_CCO-22-15

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations,	None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	None
	testimony	
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or	None
	pending	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non-	None
	financial interests	

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date: 2/3/2022

Your Name: \_\_ Susan C. Pannullo

Manuscript Title: Novel Approaches to the Management of Patients with 5-15 Brain Metastases: A Narrative Review\_

Manuscript number (if known):\_\_CCO-22-15

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	Novocure	consulting

5	Payment or honoraria for	None	
,	lectures, presentations,	Tione .	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
	,		
7	Support for attending	None	
,	meetings and/or travel		
	in coming and, or craver		
_			
8	Patents planned, issued or	Pannullo S and Cantor N.	Patent issued
	pending	US Patent # 6,750,007:	
		"Dehydration Detection	
		Device and Method of	
		Use." Filed March 6, 2002;	
		awarded June 15, 2004.	
		Assignee: Arrow	
		Development Corp.	
		Chidambaram S, Pannullo	Provisional patent filed
		SC, Palumbo MC, Stifano	
		V, McKenna JT, Redaelli A,	
		Olivi A. NeuroVis: An	
		Application for bringing	
		mixed reality into	
		interdisciplinary case	
		discussions in	
		neurosurgery and	
		radiosurgery. Provisional	
		patent # 63/091,673. Filed	
		Oct 14, 2020. Full patent	
		submitted Oct 14, 2021.	
		Pannullo S,	Provisional patent filed
		Cheeseborough J, Miller J,	
		Thornton KD, Shwetha S,	
		Webb TN, Kim S, Zappi K.	
		External Cranial Prosthesis	
		for Craniectomy Defect.	
		Provisional Patent #	
		63/189,821. Filed May 18,	
0	Double on the control of the control	2021.	
9	Participation on a Data	None	
	Safety Monitoring Board or		
4.5	Advisory Board		
10	Leadership or fiduciary role	Chair, Board of Trustees,	
	in other board, society,	TheWashington Center	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	

12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

SCP reports patent issued "Pannullo S and Cantor N. US Patent # 6,750,007: "Dehydration Detection Device and Method of Use." Filed March 6, 2002; awarded June 15, 2004. Assignee: Arrow Development Corp."; provisional patent filed "Chidambaram S, Pannullo SC, Palumbo MC, Stifano V, McKenna JT, Redaelli A, Olivi A. NeuroVis: An Application for bringing mixed reality into interdisciplinary case discussions in neurosurgery and radiosurgery. Provisional patent # 63/091,673. Filed Oct 14, 2020. Full patent submitted Oct 14, 2021."; and provisional patent filed "Pannullo S, Cheeseborough J, Miller J, Thornton KD, Shwetha S, Webb TN, Kim S, Zappi K. External Cranial Prosthesis for Craniectomy Defect. Provisional Patent # 63/189,821. Filed May 18, 2021."; and Chair,Board of Trustees, TheWashington Center.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2/3/2022

Your Name:\_\_ Jonathan P.S. Knisely

Manuscript Title: Novel Approaches to the Management of Patients with 5-15 Brain Metastases: A Narrative Review\_

Manuscript number (if known):\_\_CCO-22-15

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
3	Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	None  None	36 months
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations,	None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	None
	testimony	
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or	None
	pending	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non-	None
	financial interests	

None.	

Please place an "X" next to the following statement to indicate your agreement: